SCHEMBL10099586

SCHEMBL10099586

COc1cccc(C(=O)NC2(C(=O)O)CCCCC2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR132 Q9UNW8 1/20 0.60
ALDH1A1 P00352 2/20 0.57
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
FAAH O00519 1/20 0.56
CNR2 P34972 1/20 0.56
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
GAA P10253 1/20 0.55
KCNK3 O14649 1/20 0.54
KCNK9 Q9NPC2 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
LPAR1 Q92633 1/20 0.53
RXFP1 Q9HBX9 1/20 0.51
POLB P06746 1/20 0.51
CTSL P07711 1/20 0.51
CTSB P07858 1/20 0.51
CTSS P25774 1/20 0.51
TP53 P04637 1/20 0.50
NLRP3 Q96P20 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18059055 0.90 ALDH1A1 (0.60) ALDH1A1MEN1KMT2AFAAHCNR2
SCHEMBL12023771 0.85 MEN1 (0.54) ALDH1A1MEN1KMT2AFAAHCNR2
SCHEMBL18059071 0.85 ALDH1A1 (0.55) GPR132ALDH1A1MEN1KMT2AFAAH
SCHEMBL10099592 0.84 GAA (0.60) ALDH1A1MEN1KMT2AFAAHCNR2
SCHEMBL1841973 0.83 CNR2 (0.52) ALDH1A1MEN1KMT2AFAAHCNR2
SCHEMBL10099557 0.81 MEN1 (0.55) ALDH1A1MEN1KMT2AFAAHCNR2
SCHEMBL1836676 0.80 CTSK (0.61) GPR132ALDH1A1FAAHCTSLCTSB
SCHEMBL13753631 0.79 MEN1 (0.63) ALDH1A1MEN1KMT2AFAAHCNR2
SCHEMBL12023859 0.77 GAA (0.46) ALDH1A1MEN1KMT2AFAAHCNR2
SCHEMBL1838741 0.77 PYGL (0.50) GPR132ALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093227-B2 Monosaccharide compounds and methods therefor ALCHEMIA PTY LTD (AU) 2012-01-10 US disclosed
US-8093227-B2 Monosaccharide compounds and methods therefor ALCHEMIA PTY LTD (AU) 2012-01-10 US disclosed
US-20100184607-A1 MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR ALCHEMIA PTY LTD. (AU) 2010-07-22 US disclosed
US-20100184607-A1 MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR ALCHEMIA PTY LTD. (AU) 2010-07-22 US disclosed
US-7417129-B2 Combinatorial libraries of monosaccharides ALCHEMIA PTY LTD (AU) 2008-08-26 US disclosed
US-7417129-B2 Combinatorial libraries of monosaccharides ALCHEMIA PTY LTD (AU) 2008-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184607-A1 MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR SLC5A1, UGGT1, MRPL21 GPR132 858/4885ALDH1A1 912/4885MEN1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.